Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel

Biomaterials

Volumn 32, Issue 15, 2011, Pages 3862-3874

  Eldar Boock, Anat ^a   Miller, Keren ^a   Sanchis, Joaquin ^b   Lupu, Ruth ^c   Vicent, María J ^b   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^c MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Integrin; Paclitaxel; Polyglutamic acid; Polymer therapeutics; RGD peptidomimetic

Indexed keywords

ANGIOGENESIS; INTEGRIN; PACLITAXEL; PEPTIDOMIMETICS; POLYGLUTAMIC ACIDS; POLYMER THERAPEUTICS;

BEARINGS (STRUCTURAL); DISEASES; DRUG DELIVERY; DRUG DOSAGE; FUNCTIONAL POLYMERS; POLYMERS; SELF ASSEMBLY; TUMORS;

ENDOTHELIAL CELLS;

INTEGRIN; PACLITAXEL; PEPTIDOMIMETIC AGENT; POLYGLUTAMIC ACID; VITRONECTIN RECEPTOR;

ARTICLE; CANCER CELL; CELL MIGRATION; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATHEPSIN B; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRINS; MICE; MICE, INBRED BALB C; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PACLITAXEL; POLYGLUTAMIC ACID; RATS; RATS, WISTAR;

MUS;

EID: 79952745545     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.01.073     Document Type: Article

References (42)

1. Folkman J. History of angiogenesis. Angiogenesis: an integrative approach from science to medicine 2008, 1-14. Springer-Verlag, Heidelberg, Germany. W. Figg, J. Folkman (Eds.).
2. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6(4):273-286.
3. Alavi S.A., Cheresh D.A. Integrins in angiogenesis. Angiogenesis: an integrative approach from science to medicine 2008, 63-73. Springer-Verlag, Heidelberg, Germany. W. Figg, J. Folkman (Eds.).
4. Cox D., Aoki T., Seki J., Motoyama Y., Yoshida K. The pharmacology of the integrins. Med Res Rev 1994, 14(2):195-228.
5. Avraamides C.J., Garmy-Susini B., Varner J.A. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008, 8(8):604-617.
6. Stromblad S., Cheresh D.A. Integrins, angiogenesis and vascular cell survival. Chem Biol 1996, 3(11):881-885.
7. Bazzoni G., Dejana E., Lampugnani M.G. Endothelial adhesion molecules in the development of the vascular tree: the garden of forking paths. Curr Opin Cell Biol 1999, 11(5):573-581.
8. Lohof E., Planker E., Mang C., Burkhart F., Dechantsreiter M.A., Haubner R., et al. Carbohydrate derivatives for use in drug design:cyclic alpha(v)-selective RGD peptides. Angew Chem Int Ed Engl 2000, 39(15):2761-2764.
9. Monferran S., Skuli N., Delmas C., Favre G., Bonnet J., Cohen-Jonathan-Moyal E., et al. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int J Cancer 2008, 123(2):357-364.
10. Felding-Habermann B., Mueller B.M., Romerdahl C.A., Cheresh D.A. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 1992, 89(6):2018-2022.
11. Wang J., Lou P., Lesniewski R., Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003, 14(1):13-19.
12. Miele E., Spinelli G.P., Miele E., Tomao F., Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009, 4:99-105.
13. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006, 7(8):1041-1053.
14. Miller K., Erez R., Segal E., Shabat D., Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl 2009, 48(16):2949-2954.
15. Langer C.J., O'Byrne K.J., Socinski M.A., Mikhailov S.M., Lesniewski-Kmak K., Smakal M., et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008, 3(6):623-630.
16. Paz-Ares L., Ross H., O'Brien M., Riviere A., Gatzemeier U., Von Pawel J., et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008, 98(10):1608-1613.
17. O'Brien M.E., Socinski M.A., Popovich A.Y., Bondarenko I.N., Tomova A., Bilynsky B.T., et al. Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008, 3(7):728-734.
18. Buescher J.M., Margaritis A. Microbial biosynthesis of polyglutamic acid biopolymer and applications in the biopharmaceutical, biomedical and food industries. Crit Rev Biotechnol 2007, 27(1):1-19.
19. Duncan R., Ferruti P., Sgouras D., Tuboku-Metzger A., Ranucci E., Bignotti F. A polymer-Triton X-100 conjugate capable of PH-dependent red blood cell lysis: a model system illustrating the possibility of drug delivery within acidic intracellular compartments. J Drug Target 1994, 2(4):341-347.
20. Vicent M.J., Perez-Paya E. Poly-L-glutamic acid (PGA) aided inhibitors of apoptotic protease activating factor 1 (Apaf-1): an antiapoptotic polymeric nanomedicine. J Med Chem 2006, 49(13):3763-3765.
21. Strojnik T., Zajc I., Bervar A., Zidanik B., Golouh R., Kos J., et al. Cathepsin B and its inhibitor stefin A in brain tumors. Pflugers Arch 2000, 439(3 Suppl):R122-R123.
22. Strojnik T., Kos J., Zidanik B., Golouh R., Lah T. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin Cancer Res 1999, 5(3):559-567.
23. Decock J., Obermajer N., Vozelj S., Hendrickx W., Paridaens R., Kos J. Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. Int J Biol Markers 2008, 23(3):161-168.
24. Foekens J.A., Kos J., Peters H.A., Krasovec M., Look M.P., Cimerman N., et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 1998, 16(3):1013-1021.
25. Haag R., Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 2006, 45(8):1198-1215.
26. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004, 10(3):255-261.
27. Satchi-Fainaro R., Mamluk R., Wang L., Short S.M., Nagy J.A., Feng D., et al. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 2005, 7(3):251-261.
28. Segal E., Pan H., Ofek P., Udagawa T., Kopeckova P., Kopecek J., et al. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One 2009, 4(4):e5233.
29. Curtin S.A., Deming T.J. Initiators for end-group functionalized polypeptides via tandem addition reactions. J Am Chem Soc 1999, 121(32):7427-7428.
30. Polyak D., Ryppa C., Eldar-Boock A., Ofek P., Many A., Licha K., et al. Development of PEGylated doxorubicin-E-[c(RGDfK)2] conjugate for integrin-targeted cancer therapy. Polym Adv Technol 2011, 22:103-113.
31. Ryppa C., Mann-Steinberg H., Biniossek M.L., Satchi-Fainaro R., Kratz F. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3. Int J Pharm 2009, 368(1-2):89-97.
32. Liu Z., Chen K., Davis C., Sherlock S., Cao Q., Chen X., et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008, 68(16):6652-6660.
33. Dechantsreiter M.A., Planker E., Matha B., Lohof E., Holzemann G., Jonczyk A., et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999, 42(16):3033-3040.
34. Aumailley M., Gurrath M., Muller G., Calvete J., Timpl R., Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991, 291(1):50-54.
35. NIH. Available from: http://clinicaltrials.gov/search/intervention%3DCilengitide.
36. Paolillo M., Russo M.A., Serra M., Colombo L., Schinelli S. Small molecule integrin antagonists in cancer therapy. Mini Rev Med Chem 2009, 9(12):1439-1446.
37. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10(1):9-22.
38. Reynolds A.R., Hart I.R., Watson A.R., Welti J.C., Silva R.G., Robinson S.D., et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009, 15(4):392-400.
39. Mitra A., Mulholland J., Nan A., McNeill E., Ghandehari H., Line B.R. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release 2005, 102(1):191-201.
40. Park K., Kim Y.S., Lee G.Y., Park R.W., Kim I.S., Kim S.Y., et al. Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth. Pharm Res 2008, 25(12):2786-2798.
41. Ryppa C., Mann-Steinberg H., Fichtner I., Weber H., Satchi-Fainaro R., Biniossek M.L., et al. In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3. Bioconjug Chem 2008.
42. Vellon L., Menendez J.A., Liu H., Lupu R. Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner. Differentiation 2007, 75(9):819-830.